

Manfred P Wirth

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3877198/manfred-p-wirth-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

2,723
citations

27
h-index

49
g-index

131
ext. papers

3,306
ext. citations

5.3
avg, IF

4.73
L-index

#	Paper	IF	Citations
125	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study.. <i>World Journal of Urology</i> , 2022 , 1	4	1
124	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2021 ,	6.7	3
123	The Clinical Complexity of Penile Cancer: Current Clinical-Epidemiological Data from the Database of the Free State of Saxony/Germany. <i>Urologia Internationalis</i> , 2021 , 1-10	1.9	0
122	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. <i>Cells</i> , 2021 , 10,	7.9	2
121	Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria. <i>Urologia Internationalis</i> , 2021 , 105, 278-284	1.9	6
120	OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancer: A phase II trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 115-115	2.2	1
119	Decreasing Non-bladder-cancer Mortality After Radical Cystectomy. <i>European Urology Open Science</i> , 2021 , 29, 15-18	0.9	
118	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , 2021 , 80, 703-711	10.2	16
117	The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
116	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020 , 78, 21-28	10.2	141
115	Quantifying the Relationship Between Increasing Life Expectancy and Nonprostate Cancer Mortality After Radical Prostatectomy. <i>Urology</i> , 2020 , 142, 174-178	1.6	3
114	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
113	Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy. <i>Urologia Internationalis</i> , 2020 , 104, 567-572	1.9	3
112	ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. <i>European Urology</i> , 2020 , 78, 452-459	10.2	4
111	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 678-678	2.2	2
110	and DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
109	Socioeconomic Status-Related Parameters as Predictors of Competing (Non-Bladder Cancer) Mortality after Radical Cystectomy. <i>Urologia Internationalis</i> , 2020 , 104, 62-69	1.9	2

108	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. <i>Diagnostics</i> , 2020 , 10,	3.8	6
107	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020 , 78, 43-59	10.2	13
106	Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?. <i>World Journal of Urology</i> , 2020 , 38, 695-702	4	4
105	External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 145-150	4.2	2
104	In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014. <i>Urologia Internationalis</i> , 2019 , 102, 284-292	1.9	8
103	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 368-380	10.2	26
102	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 142-150	10.2	51
101	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019 , 76, 179-186	10.2	10
100	Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. <i>Urologia Internationalis</i> , 2019 , 102, 20-26	1.9	4
99	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix Letter to the Editor re: Fabian Lohaus, Klaus Z̄phel, Steffen L̄rk, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? <i>Eur Urol</i> 2019;75:548-51. <i>European Urology</i> , 2019 , 76, e103-e104	10.2	
98	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. <i>Urologia Internationalis</i> , 2019 , 103, 427-432	1.9	3
97	Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20661-e20661 ⁴	2.2	14
96	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019 , 2, 265-273	6.7	44
95	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019 , 75, 548-551	10.2	22
94	Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. <i>Clinical Biochemistry</i> , 2019 , 64, 60-63	3.5	24
93	Online support groups offer low-threshold backing for family and friends of patients with prostate cancer. <i>European Journal of Cancer Care</i> , 2019 , 28, e12982	2.4	2
92	Penile cancer - Incidence, mortality, and survival in Saxony, Germany. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 295.e1-295.e8	2.8	9
91	Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. <i>Urologia Internationalis</i> , 2019 , 102, 96-101	1.9	8

90	Validation of the Preoperative Score to Predict Postoperative Mortality in Patients Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2019 , 5, 197-200	5.1	9
89	Only . <i>European Urology Focus</i> , 2019 , 5, 361-364	5.1	6
88	Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3502-3509	3.1	14
87	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. <i>Urologia Internationalis</i> , 2018 , 100, 155-163	1.9	8
86	Chronically Infected Urachal Remnant Mimicking Tumor With Peritoneal Carcinomatosis. <i>Urology</i> , 2018 , 116, e3-e4	1.6	
85	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018 , 4, 252-259	5.1	12
84	Selection Effects May Explain Smoking-related Outcome Differences After Radical Cystectomy. <i>European Urology Focus</i> , 2018 , 4, 395-398	5.1	2
83	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients. <i>BJU International</i> , 2018 , 121, 53-60	5.6	35
82	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 11.e1-11.e6	2.8	7
81	Quantification of MicroRNAs in Urine-Derived Specimens. <i>Methods in Molecular Biology</i> , 2018 , 1655, 201-226	2.2	11
80	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018 , 74, 357-368	10.2	72
79	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. <i>Oncotarget</i> , 2018 , 9, 27293-27304	3.3	17
78	Local ablative radiotherapy: A means to revert low volume castration-resistant prostate cancer into a hormone-sensitive status?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 188-188	2.2	
77	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018 , 1, 91-100	6.7	34
76	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. <i>BMC Urology</i> , 2018 , 18, 91	2.2	8
75	Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2018 , 74, 644-650	10.2	38
74	Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. <i>World Journal of Urology</i> , 2017 , 35, 245-250	4	6
73	Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. <i>Urology</i> , 2017 , 101, e5-e6	1.6	11

72	Delayed Radiographic Manifestation of Renal Pseudoaneurysms After Blunt Trauma. <i>Urology</i> , 2017 , 103, e9-e10	1.6	
71	Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. <i>European Urology</i> , 2017 , 72, 424-431	10.2	114
70	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1757-1769	4.9	8
69	High volume is the key for improving in-hospital outcomes after radical prostatectomy: a total population analysis in Germany from 2006 to 2013. <i>World Journal of Urology</i> , 2017 , 35, 1045-1053	4	27
68	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. <i>BMC Cancer</i> , 2017 , 17, 790	4.8	11
67	Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation. <i>Beilstein Journal of Nanotechnology</i> , 2017 , 8, 1307-1317	3	9
66	Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of E-catenin in prostate cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 2201-2210	4.9	5
65	Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older. <i>European Urology</i> , 2017 , 71, 710-713	10.2	9
64	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 356-362	3.3	22
63	PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. <i>Case Reports in Urology</i> , 2017 , 2017, 1654231	0.5	11
62	Level of education and mortality after radical prostatectomy. <i>Asian Journal of Andrology</i> , 2017 , 19, 173-178		4
61	Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. <i>European Urology</i> , 2016 , 69, 984-7	10.2	20
60	MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2249-61	4.9	23
59	Renal Sarcoidosis Mimicking Xanthogranulomatous Pyelonephritis. <i>Urology</i> , 2016 , 97, e19-e20	1.6	4
58	Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 432.e1-8	2.8	6
57	Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. <i>BJU International</i> , 2016 , 117, 272-9	5.6	25
56	Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. <i>Eur Urol</i> 2015;68:805-11. <i>European Urology</i> , 2016 , 69, e130	10.2	
55	Growth of a Level III Vena Cava Tumor Thrombus Within 1 Month. <i>Urology</i> , 2016 , 90, e1-2	1.6	11

54	Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 1123-9	4	15
53	Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1171-82	4.9	13
52	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. <i>Cancer Research</i> , 2016 , 76, 2637-51	10.1	48
51	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21-30. <i>European Urology</i> , 2016 , 70, e9	10.2	
50	Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 401-14	4.9	12
49	β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in α-Adrenoceptor Knockout Mice. <i>Frontiers in Pharmacology</i> , 2016 , 7, 118	5.6	3
48	Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy. <i>BJU International</i> , 2016 , 118, 213-20	5.6	48
47	Androgen Deprivation Therapy and Alzheimer Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2801	2.2	5
46	Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. <i>Oncology Letters</i> , 2016 , 12, 3143-3152	2.6	7
45	Re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>Eur Urol</i> 2015;68:756-65. <i>European Urology</i> , 2016 , 69, e128	10.2	
44	Validation of an Age-adjusted Prostate Cancer-Specific Comorbidity Index. <i>European Urology</i> , 2016 , 69, 764-6	10.2	12
43	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. <i>Urology</i> , 2016 , 94, e1-2	1.6	7
42	Should the Urologist Treat Castration Resistant Prostate Cancer? Yes. <i>Journal of Urology</i> , 2015 , 194, 2862.5		1
41	Re: Syed Johar Raza, Timothy Wilson, James O. Peabody, et al. Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Eur Urol</i> 2015;68:721-8. <i>European Urology</i> , 2015 , 68, e109	10.2	2
40	Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038 . <i>European Urology</i> , 2015 , 68, e103	10.2	2
39	Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. <i>Eur Urol</i> 2015;67:212-9: Extended Lymph Node Dissection and the Will Rogers Phenomenon. <i>European Urology</i> , 2015 , 67, e112	10.2	1
38	Mucosa of murine detrusor impairs α-adrenoceptor-mediated relaxation. <i>Neurourology and Urodynamics</i> , 2015 , 34, 592-7	2.3	4
37	Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. <i>BJU International</i> , 2015 , 116, 93-101	5.6	94

36	Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells. <i>International Journal of Oncology</i> , 2015 , 47, 1121-30	4.4	6
35	Aldehyde Dehydrogenase Is Regulated by β Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , 2015 , 75, 1482-94	10.1	157
34	Characterization of different carbon nanotubes for the development of a mucoadhesive drug delivery system for intravesical treatment of bladder cancer. <i>International Journal of Pharmaceutics</i> , 2015 , 479, 357-63	6.5	34
33	Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy. <i>European Urology</i> , 2014 , 66, 987-90	10.2	26
32	Testing of a novel easy-to-use mortality index in a radical prostatectomy cohort. <i>Urology</i> , 2014 , 84, 307-126		3
31	Reply: To PMID 24962844. <i>Urology</i> , 2014 , 84, 312-3	1.6	2
30	European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. <i>European Urology</i> , 2014 , 66, 628-32	10.2	54
29	Re: Zhu et al.: The expression and evaluation of androgen receptor in human renal cell carcinoma (Urology 2014;83:510.e19-24). <i>Urology</i> , 2014 , 84, 734-5	1.6	1
28	Does increasing life expectancy affect competing mortality after radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 413-8	2.8	6
27	Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. <i>European Urology</i> , 2014 , 66, 156-63	10.2	114
26	Re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. <i>Eur Urol</i> 2014;65:20-5. <i>European Urology</i> , 2014 , 65, e24	10.2	1
25	Re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. <i>Eur Urol</i> 2014;66:666-72. <i>European Urology</i> , 2014 , 66, e85	10.2	0
24	The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. <i>European Urology</i> , 2014 , 66, 191-9	10.2	76
23	Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2014 , 9, e102262	3.7	15
22	Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2014 , 7, 645-54	4.4	6
21	Re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. <i>Eur Urol</i> 2014;66:156-163. <i>European Urology</i> , 2014 , 66, e13	10.2	0
20	Dendritic cell-based immunotherapy for prostate cancer. <i>Clinical and Developmental Immunology</i> , 2010 , 2010, 517493		53
19	Functionalization of carbon encapsulated iron nanoparticles. <i>Journal of Nanoparticle Research</i> , 2010 , 12, 513-519	2.3	29

18	Words of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. <i>European Urology</i> , 2010 , 58, 939-40	10.2	2
17	Words of wisdom. Re: utilization and outcomes of minimally invasive radical prostatectomy. <i>European Urology</i> , 2008 , 54, 1439-40	10.2	2
16	Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. <i>Frontiers of Radiation Therapy and Oncology</i> , 2008 , 41, 39-48		14
15	Hormone-refractory prostate cancer: what have we learned?. <i>BJU International</i> , 2007 , 100 Suppl 2, 56-9	5.6	3
14	Antiandrogens in the treatment of prostate cancer. <i>European Urology</i> , 2007 , 51, 306-13; discussion 314	10.2	70
13	Optimal treatment of locally advanced prostate cancer. <i>World Journal of Urology</i> , 2007 , 25, 169-76	4	18
12	Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. <i>Prostate</i> , 2006 , 66, 811-21	4.2	100
11	Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. <i>European Urology</i> , 2004 , 45, 267-70; discussion 270	10.2	75
10	Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. <i>Journal of Urology</i> , 2004 , 172, 1865-70	2.5	168
9	Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. <i>Prostate</i> , 2003 , 56, 270-9	4.2	40
8	Value of endocrine therapy for early and locally advanced prostate cancer. <i>Drugs and Aging</i> , 2003 , 20, 115-24	4.7	3
7	Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program. <i>Oncology</i> , 2003 , 65 Suppl 1, 1-4	3.6	3
6	Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. <i>International Journal of Cancer</i> , 2002 , 102, 390-7	7.5	62
5	Perspectives in adjuvant treatment of prostate cancer. <i>Urologia Internationalis</i> , 2002 , 68, 1-5	1.9	2
4	The Management of Localized or Locally Advanced Prostate Cancer. <i>American Journal of Cancer</i> , 2002 , 1, 387-396		1
3	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program. <i>Journal of Urology</i> , 2002 , 168, 429-435	2.5	188
2	Author reply. <i>Cancer</i> , 2000 , 88, 2196-2197	6.4	
1	Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. <i>Prostate</i> , 1998 , 36, 85-91	4.2	70

